Pharmaceuticals

Conjugate Vaccine Industry Anticipated to Expand at 12.4% CAGR During the Forecast Period

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Conjugate Vaccine Market By 2029?

The conjugate vaccine market size has experienced significant expansion in recent years. This market is projected to expand from $18.9 billion in 2024 to $21.26 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.5%. Historically, this growth can be linked to factors such as disease burden, the implementation of government immunization programs, heightened awareness, a strong focus on pediatric vaccination, and prevailing preventive healthcare trends.

The conjugate vaccine market is anticipated to experience substantial expansion in the coming years. It is projected to grow to “$33.99 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 12.4%. This market growth during the forecast period can be attributed to factors such as broadening immunization policies, evolving aging population dynamics, novel vaccine indications, increasing global health security concerns, enhanced international collaboration, and the influence of economic development. Prominent trends expected in this timeframe include alliances and partnerships for vaccine distribution, tailored strategies for high-risk populations, applications in emerging infectious diseases, advancements in vaccine manufacturing technologies, and global health initiatives promoting vaccine equity.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

Which Industry Drivers Are Expected To Accelerate The Conjugate Vaccine Market From 2025 To 2029?

The expanded application of conjugate vaccines in adults is anticipated to fuel the expansion of the conjugate vaccine market. These vaccines are engineered to elicit a robust immune reaction targeting bacterial capsular polysaccharides, thereby strengthening the body’s protective systems against bacterial pathogens. Administering conjugate vaccines to adults contributes to lowering the likelihood of serious sickness, associated complications, and the spread of such bacterial ailments through the induction of a strong immune response. For example, in June 2024, data released by the UK Health Security Agency (UKHSA), a public health body in the UK, indicated that the ‘6-in-1’ vaccine coverage over a 12-month period in the UK remained consistent at 91.7%. Coverage for the initial dose of the pneumococcal conjugate vaccine (PCV) stayed at 93.7%. Rotavirus vaccine coverage experienced a 0.6% rise, reaching 89.3%, concurrently, the second dose of the meningitis B vaccine (MenB2) saw an increment of 0.1% to 91.5%. Consequently, the growing adoption of conjugate vaccines for adults is propelling the expansion of the conjugate vaccine market.

What Are The Emerging Segments Gaining Attention In The Conjugate Vaccine Market?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

What Trends Are Redefining The Conjugate Vaccine Market Dynamics?

A significant trend observed in the conjugate vaccine market is the increasing focus on innovation within this vaccine category. Companies involved in the conjugate vaccine sector are prioritizing the creation of novel conjugate vaccines to maintain their competitive edge. As an illustration, Pfizer Inc., a pharmaceutical and biotechnology firm based in the US, introduced Prevnar 20, a 20-valent pneumococcal conjugate vaccine, in Canada during June 2022. This launch aimed at preventing pneumonia and invasive pneumococcal infections in individuals 18 years of age and above. Prevnar 20 incorporates conjugates addressing the 13 serotypes already addressed by PREVNAR 13, alongside conjugates for an additional seven serotypes. These additional serotypes are linked to invasive pneumococcal disease, elevated case-fatality rates, antimicrobial resistance, and meningitis.

Who Are The Top Performing Companies In The Conjugate Vaccine Market In Recent Years?

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

What Regional Growth Trends Are Shaping The Conjugate Vaccine Market Outlook?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Conjugate Vaccine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

Browse Through More Reports Similar to the Global Conjugate Vaccine Market 2025, By The Business Research Company

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Dtp Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795